BACKGROUND:Gastric antral vascular ectasia (GAVE) is characterized by mucosal and submucosal vascular ectasia causing recurrent hemorrhage and thus, chronic anemia, in patients with cirrhosis. Treatment with argon plasma coagulation (APC) is an effective and safe method, but requires multiple sessions of endoscopic therapy. Endoscopic band ligation (EBL) was found to be a good alternative for APC as a treatment for GAVE, especially in refractory cases. The aim of this prospective randomized controlled study was to evaluate the safety and efficacy of EBL, as compared to APC, in the treatment of GAVE and gastric fundal vascular ectasia (GFVE). PATIENTS AND METHODS: A total of 88 cirrhotic patients with GAVE were prospectively randomized to endoscopic treatment with either EBL or APC, every 2 weeks until complete obliteration was accomplished; then they were followed up endoscopically after 6 months, plus they had monthly measurement of hemoglobin levels during that period. RESULTS: We describe the presence of mucosal and submucosal lesions in the gastric fundal area that were similar to those found in GAVE in 13 patients (29.5%) of the EBL group and 9 patients (20.5%) of the APC group; we named this GFVE. In these cases, we treated the fundal lesions with the same techniques we had used for treating GAVE, according to the randomization. We found that EBL significantly decreased the number of sessions required for complete obliteration of the lesions (2.98 sessions compared to 3.48 sessions in the APC group (p < 0.05)). Hemoglobin levels increased significantly after obliteration of the lesions in both groups, compared to pretreatment values (p < 0.05), but with no significant difference between the two groups (p > 0.05); however, the EBL group of patients required a significantly smaller number of units of blood transfusion than the APC group of patients (p < 0.05). There were no significant differences in adverse events nor complications between the two groups (p > 0.05). CONCLUSIONS: This study described and histologically proved the presence of GFVE occurring comcomitantly with GAVE in cirrhotic patients. We showed that GFVE can be successfully managed by EBL or APC. Our study revealed that EBL is more effective and is comparable in safety to APC, in the treatment of GAVE and GFVE in cirrhotic patients.
RCT Entities:
BACKGROUND: Gastric antral vascular ectasia (GAVE) is characterized by mucosal and submucosal vascular ectasia causing recurrent hemorrhage and thus, chronic anemia, in patients with cirrhosis. Treatment with argon plasma coagulation (APC) is an effective and safe method, but requires multiple sessions of endoscopic therapy. Endoscopic band ligation (EBL) was found to be a good alternative for APC as a treatment for GAVE, especially in refractory cases. The aim of this prospective randomized controlled study was to evaluate the safety and efficacy of EBL, as compared to APC, in the treatment of GAVE and gastric fundal vascular ectasia (GFVE). PATIENTS AND METHODS: A total of 88 cirrhotic patients with GAVE were prospectively randomized to endoscopic treatment with either EBL or APC, every 2 weeks until complete obliteration was accomplished; then they were followed up endoscopically after 6 months, plus they had monthly measurement of hemoglobin levels during that period. RESULTS: We describe the presence of mucosal and submucosal lesions in the gastric fundal area that were similar to those found in GAVE in 13 patients (29.5%) of the EBL group and 9 patients (20.5%) of the APC group; we named this GFVE. In these cases, we treated the fundal lesions with the same techniques we had used for treating GAVE, according to the randomization. We found that EBL significantly decreased the number of sessions required for complete obliteration of the lesions (2.98 sessions compared to 3.48 sessions in the APC group (p < 0.05)). Hemoglobin levels increased significantly after obliteration of the lesions in both groups, compared to pretreatment values (p < 0.05), but with no significant difference between the two groups (p > 0.05); however, the EBL group of patients required a significantly smaller number of units of blood transfusion than the APC group of patients (p < 0.05). There were no significant differences in adverse events nor complications between the two groups (p > 0.05). CONCLUSIONS: This study described and histologically proved the presence of GFVE occurring comcomitantly with GAVE in cirrhotic patients. We showed that GFVE can be successfully managed by EBL or APC. Our study revealed that EBL is more effective and is comparable in safety to APC, in the treatment of GAVE and GFVE in cirrhotic patients.
Authors: Eric M Ward; Massimo Raimondo; Barry G Rosser; Michael B Wallace; Rolland D Dickson Journal: J Clin Gastroenterol Date: 2004 Nov-Dec Impact factor: 3.062
Authors: Christopher D Wells; M Edwyn Harrison; Suryakanth R Gurudu; Michael D Crowell; Thomas J Byrne; Giovanni Depetris; Virender K Sharma Journal: Gastrointest Endosc Date: 2008-06-03 Impact factor: 9.427
Authors: Sarah Cho; Simon Zanati; Elaine Yong; Maria Cirocco; Gabor Kandel; Paul Kortan; Gary May; Norman Marcon Journal: Gastrointest Endosc Date: 2008-07-21 Impact factor: 9.427
Authors: Rajesh Mandhwani; Farina M Hanif; Muhammad Manzoor Ul Haque; Rajesh Kumar Wadhwa; Nasir Hassan Luck; Muhammad Mubarak Journal: J Transl Int Med Date: 2017-09-30
Authors: Cormac Magee; Gideon Lipman; Durayd Alzoubaidi; Martin Everson; Rami Sweis; Matthew Banks; David Graham; Charles Gordon; Laurence Lovat; Charles Murray; Rehan Haidry Journal: United European Gastroenterol J Date: 2018-11-15 Impact factor: 4.623
Authors: Mansour A Parsi; Allison R Schulman; Harry R Aslanian; Manoop S Bhutani; Kuman Krishnan; David R Lichtenstein; Joshua Melson; Udayakumar Navaneethan; Rahul Pannala; Amrita Sethi; Guru Trikudanathan; Arvind J Trindade; Rabindra R Watson; John T Maple Journal: VideoGIE Date: 2019-06-27
Authors: Jean M Chalhoub; Jalaluddin Umar; Kevin Groudan; Nour Hamadeh; David J Desilets; Yesenia Greeff Journal: United European Gastroenterol J Date: 2021-02-18 Impact factor: 4.623